Aliskiren: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
Line 381: | Line 381: | ||
{{PillImage | {{PillImage | ||
|fileName=Aliskiren001.jpg|This image is provided by the National Library of Medicine. | |fileName=Aliskiren001.jpg|This image is provided by the National Library of Medicine. | ||
|drugName= | |drugName=Aliskiren 150 mg oral tablet | ||
|NDC=00078-0485-15 | |NDC=00078-0485-15 | ||
|drugAuthor= | |drugAuthor= | ||
|ingredients= | |ingredients=Aliskiren | ||
|pillImprint= | |pillImprint=NVR;IL | ||
|dosageValue= | |dosageValue=150 | ||
|dosageUnit= | |dosageUnit=mg | ||
|pillColor= | |pillColor=Pink | ||
|pillShape= | |pillShape=Round | ||
|pillSize= | |pillSize=11 | ||
|pillScore= | |pillScore= | ||
}} | }} | ||
Line 396: | Line 396: | ||
{{PillImage | {{PillImage | ||
|fileName=Aliskiren002.jpg|This image is provided by the National Library of Medicine. | |fileName=Aliskiren002.jpg|This image is provided by the National Library of Medicine. | ||
|drugName= | |drugName=Aliskiren 150 mg oral tablet | ||
|NDC=00078-0486-15 | |NDC=00078-0486-15 | ||
|drugAuthor= | |drugAuthor= | ||
|ingredients= | |ingredients=Aliskiren | ||
|pillImprint= | |pillImprint=NVR;IU | ||
|dosageValue= | |dosageValue=150 | ||
|dosageUnit= | |dosageUnit=mg | ||
|pillColor= | |pillColor=Red | ||
|pillShape= | |pillShape=Oval | ||
|pillSize= | |pillSize=18 | ||
|pillScore= | |pillScore= | ||
}} | }} |
Revision as of 12:25, 2 July 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gerald Chi
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Black Box Warning
WARNING: FETAL TOXICITY
See full prescribing information for complete Boxed Warning.
* When pregnancy is detected, discontinue Tekturna as soon as possible.
|
Overview
Aliskiren is a renin inhibitor that is FDA approved for the {{{indicationType}}} of hypertension. There is a Black Box Warning for this drug as shown here. Common adverse reactions include diarrhea, dizziness, headache, and elevated serum creatinine.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Hypertension
- Dosing Information
- Dosage
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
Condition1
- Developed by:
- Class of Recommendation:
- Strength of Evidence:
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Aliskiren in adult patients.
Non–Guideline-Supported Use
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Aliskiren in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding FDA-Labeled Use of Aliskiren in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition1
- Developed by:
- Class of Recommendation:
- Strength of Evidence:
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Aliskiren in pediatric patients.
Non–Guideline-Supported Use
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Aliskiren in pediatric patients.
Contraindications
- Condition1
Warnings
WARNING: FETAL TOXICITY
See full prescribing information for complete Boxed Warning.
* When pregnancy is detected, discontinue Tekturna as soon as possible.
|
Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Aliskiren in the drug label.
Central Nervous System
Cardiovascular
Respiratory
Gastrointestinal
Hypersensitivity
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Aliskiren in the drug label.
Central Nervous System
Cardiovascular
Respiratory
Gastrointestinal
Hypersensitivity
Miscellaneous
Drug Interactions
- Drug
- Description
Use in Specific Populations
Pregnancy
- Pregnancy Category
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Aliskiren in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Aliskiren during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Aliskiren with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Aliskiren with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Aliskiren with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Aliskiren with respect to specific gender populations.
Race
There is no FDA guidance on the use of Aliskiren with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Aliskiren in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Aliskiren in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Aliskiren in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Aliskiren in patients who are immunocompromised.
Administration and Monitoring
Administration
Oral
Intravenous
Monitoring
There is limited information regarding Monitoring of Aliskiren in the drug label.
Condition1
Description
IV Compatibility
There is limited information regarding IV Compatibility of Aliskiren in the drug label.
Overdosage
Acute Overdose
Signs and Symptoms
Description
Management
Description
Chronic Overdose
There is limited information regarding Chronic Overdose of Aliskiren in the drug label.
Pharmacology
There is limited information regarding Aliskiren Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Aliskiren Mechanism of Action in the drug label.
Structure
There is limited information regarding Structure of Aliskiren in the drug label.
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Aliskiren in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Aliskiren in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Aliskiren in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Aliskiren in the drug label.
Condition1
Description
How Supplied
There is limited information regarding Aliskiren How Supplied in the drug label.
Storage
There is limited information regarding Aliskiren Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Aliskiren |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Aliskiren |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Aliskiren in the drug label.
Precautions with Alcohol
Alcohol-Aliskiren interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
Tekturna®[1]
Look-Alike Drug Names
- A® — B®[2]
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ "TEKTURNA (aliskiren hemifumarate) tablet, film coated [Novartis Pharmaceuticals Corporation]".
- ↑ "http://www.ismp.org". External link in
|title=
(help)
{{#subobject:
|Page Name=Aliskiren |Pill Name=Aliskiren001.jpg |Drug Name=Aliskiren 150 mg oral tablet |Pill Ingred=Aliskiren|+sep=; |Pill Imprint=NVR;IL |Pill Dosage=150 mg |Pill Color=Pink|+sep=; |Pill Shape=Round |Pill Size (mm)=11 |Pill Scoring= |Pill Image= |Drug Author= |NDC=00078-0485-15
}}
{{#subobject:
|Page Name=Aliskiren |Pill Name=Aliskiren002.jpg |Drug Name=Aliskiren 150 mg oral tablet |Pill Ingred=Aliskiren|+sep=; |Pill Imprint=NVR;IU |Pill Dosage=150 mg |Pill Color=Red|+sep=; |Pill Shape=Oval |Pill Size (mm)=18 |Pill Scoring= |Pill Image= |Drug Author= |NDC=00078-0486-15
}}
{{#subobject:
|Label Page=Aliskiren |Label Name=No image.jpg
}}